Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Other Non-Current Assets: 2021-2024

Historic Other Non-Current Assets for China SXT Pharmaceuticals (SXTC) over the last 4 years, with Mar 2024 value amounting to $8.3 million.

  • China SXT Pharmaceuticals' Other Non-Current Assets was N/A to $8.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $8.5 million, marking a year-over-year change of. This contributed to the annual value of $8.3 million for FY2024, which is 4.88% down from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Other Non-Current Assets stood at $8.3 million for FY2024, which was down 4.88% from $8.7 million recorded in FY2023.
  • In the past 5 years, China SXT Pharmaceuticals' Other Non-Current Assets registered a high of $9.5 million during FY2022, and its lowest value of $8.3 million during FY2024.
  • Moreover, its 3-year median value for Other Non-Current Assets was $8.7 million (2023), whereas its average is $8.8 million.
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Other Non-Current Assets rose by 3.35% in 2022, and later dropped by 7.69% in 2023.
  • China SXT Pharmaceuticals' Other Non-Current Assets (Yearly) stood at $9.2 million in 2021, then rose by 3.35% to $9.5 million in 2022, then fell by 7.69% to $8.7 million in 2023, then fell by 4.88% to $8.3 million in 2024.